MannKind Corporation Reports 2024 First Quarter Financial Results: Provides Clinical Development Update
08 mai 2024 16h18 HE
|
MannKind
1Q 2024 Total revenues of $66M; +63% vs. 1Q 20231Q 2024 Net income of $11M; Non-GAAP net income of $15M$304M of cash and cash equivalents and investments at March 31, 2024In early April, repaid Midcap...
MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
06 mai 2024 06h05 HE
|
MannKind
MANNKIND RECEIVES U.S. FDA FAST TRACK DESIGNATION FOR CLOFAZIMINE INHALATION SUSPENSION FOR THE TREATMENT OF SERIOUS LUNG DISEASE
MannKind Corporation to Hold 2024 First Quarter Financial Results Conference Call on May 8, 2024
01 mai 2024 16h00 HE
|
MannKind
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2024 first quarter financial results and its management will host a...
MannKind to Proceed With Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases
30 avr. 2024 06h05 HE
|
MannKind
MannKind announced it will proceed with a Phase 1 study of nintedanib DPI (MNKD-201) for pulmonary fibrotic diseases including IPF.
MannKind Announces IND Clearance From U.S. FDA to Start Phase 3 Study of Clofazimine Inhalation Suspension for Nontuberculous Mycobacterial (NTM) Lung Disease
29 avr. 2024 06h05 HE
|
MannKind
MANNKIND ANNOUNCES IND CLEARANCE FROM U.S. FDA TO START PHASE 3 STUDY OF CLOFAZIMINE INHALATION SUSPENSION FOR NTM LUNG DISEASE
MannKind Repays Certain Debt Obligations
03 avr. 2024 06h00 HE
|
MannKind
Credit and security agreement with MidCap Financial Trust repaid in full for approximately $31.6 millionConvertible note issued to Mann Group LLC repaid in exchange for 1.5 million shares of common...
MannKind Announces CFO Transition
26 mars 2024 16h05 HE
|
MannKind
MANNKIND ANNOUNCES CFO TRANSITION
INHALE-3 Study’s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections (MDI) and Insulin Pumps
11 mars 2024 06h05 HE
|
MannKind
INHALE-3 STUDY’S INITIAL MEAL CHALLENGE RESULTS COMPARING AFREZZA® HEAD-TO-HEAD WITH MULTIPLE DAILY INJECTIONS (MDI) AND INSULIN PUMPS
MannKind Announces New Clinical Data From Inhale-3 Study to be Presented by Dr. Irl B. Hirsch at ATTD on March 8
05 mars 2024 06h05 HE
|
MannKind
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic...
MannKind Corporation Announces Participation at Upcoming Conferences
04 mars 2024 13h01 HE
|
MannKind
WESTLAKE VILLAGE, Calif. and DANBURY, Conn., March 04, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic...